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Summary 
To evaluate the therapeutic value of various antihypoten-
sive agents we investigated amezinium (AMZ; CAS 
30578-37-11 dihydroergotamine (DHE; CAS 511-12-6), 
midodrine (MDD; CAS 42 794- 76-3), and oxilofrine (OXF; 
CAS 365-26-4) in volunteers during passive orthostasis in 
a randomized double-blind study against placebo (PCB). 
Blood pressure, heart rate, and circulating catecholamines 
were determined before and after i. v. injections of the men-
tioned agents before and during 10 min of passive or-
thostasis. Echocardiography and venous Plethysmo-
graphie data were obtained during resting before and after 
the administration of the drugs. Resting heart rate de-
creased after injection of PCB, AMZ, DEE, and MDD. 
During tilting no significant changes in heart rate could 
be observed. Blood pressure remained unchanged at rest 
and during orthostasis after all agents injected. DHE and 
MDD lowered circulating noradrenaline. Echocardio-
graphy parameters were changed after administration of 
AMZ (increase in stroke volume index (SVI) and ejection 
fraction (EF)), MDD (increase in enddiastolic volume in-
dex and SVI), and OXF (incease in SVI, EF, and cardiac 
index). The venous capacity of the left lower leg was only 
significantly decreased after injection of DHE, indicating 
an increased venous tone of the leg veins. The observed 
changes in sympathetic and cardiovascular parameters 
are in agreement with their sympathomimetic actions and 
allow a differential therapeutic classification: DHE and 
MDD are suitable agents for patients with sympathotonic 
orthostatic reaction; if asympathotonic orthostatic reac-
tion occurs MDD, AMX and OXF should be recommended 
to those patients. 
Zusammenfassung 
Kardiovaskuläre Parameter und Katecholamine bei frei-
willigen Probanden während passiver Orthostase / Wir-
kung antihypotensiver Substanzen 
Bei freiwilligen Probanden wurden in einer randomisier-
ten Doppelblindstudie gegen Plazebo die 4 antihypotensiv 
wirksamen Substanzen Amezinium (AMZ; CAS 30578-
37-1), Dihydroergotamin (DHE; CAS 511-12-6), Mido-
drin (MDD; CAS 32794-76-3) und Oxilofrin (OXF; CAS 
365-26-4) während passiver Orthostase untersucht, um 
ihren therapeutischen Wert zu bestimmen. Während 
lOminütiger passiver Orthostase wurden Blutdruck, Herz-
frequenz und zirkulierende Katecholamine vor und nach 
i.v. Injektion der oben erwähnten Substanzen bestimmt. 
Echokardiographische Parameter und Venenplethysmo-
graphie wurden in Ruhe vor und nach Gabe der Substan-
zen bestimmt. Die Ruhe-Herzfrequenz nahm nach Injek-
tion von Plazebo, AMZ, DHE und MDD ab. Während 
passiver Orthostase konnten keine signifikanten Verän-
derungen der Herzfrequenz beobachtet werden. Der Blut-
druck blieb unter Ruhebedingungen und während passiver 
Orthostase nach Gabe aller Substanzen unverändert. DHE 
und MDD verminderten zirkulierendes Noradrenalin. Die 
echokardiographischen Parameter wurden nach Gabe von 
AMZ (Anstieg des Schlagvolumenindex (SVI) und der 
Auswurffraktion (EF)), Midodrin (Anstieg des enddiasto-
lischen Volumenindex und des Schlagvolumenindex) und 
Oxilofrin (Anstieg des Schlagvolumenindex, der Auswurf-
fraktion und des Herzindex) verändert. Die Venenkapa-
zität des linken Unterschenkels wurde nur nach Injektion 
von DHE signifikant vermindert, was auf einen erhöhten 
Venentonus schließen läßt. Die beobachteten Veränderun-
gen des Sympathikustonus und der kardiovaskulären Pa-
rameter stimmen mit den sympathomimetischen Wir-
kungen der Substanzen überein und erlauben eine diffe-
rentialtherapeutische Klassifizierung: DHE und MDD 
können bei Patienten mit sympathotoner orthostatischer 
Reaktion eingesetzt werden, während bei Patienten mit 
asympathotoner orthostatischer Reaktion AMZ und OXF 
bevorzugt werden. 
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1. Introduction 
Changes of body position from lying to standing lead to 
circulatory readjustments, counteracting the tendency for 
blood to pool into the legs or the splanchnic region. These 
adjustments are accompanied by a decrease in cardiac 
output, an increase in heart rate, and an increase in total 
peripheral resistance, thus maintaining arterial blood 
pressure approximately constant [14, 15]. Since circulat-
ing noradrenaline is almost doubled during erection [4], 
and sympathetic ganglionic blockade causes orthostatic 
hypotension, it is clear that sympathetic mechanisms are 
responsible for some reflex adjustments. In orthostatic 
dysregulation reflex adjustments seem to be impaired. A 
variety of drugs are administered during treatment of 
postural hypotension, mainly interfering with sympa-
thetic mechanisms in the cardiovascular system. 
Prior to the study, the drugs investigated can be charac-
terized as follows: 
Amezinium is probably an indirect acting sympathomi-
metic drug. In addition it has direct effects on a-adren-
oceptors [8]; 
Dihydroergotamine is an ergot alkaloid which possesses 
serotonergic and a-adrenergic activities [12]; 
Midodrine, a prodrug, which is converted in vivo to an 
a-sympathomimetic agent [13], and 
Oxilofrine has predominantly ß-adrenergic effects on the 
myocardium [1]. 
Therefore it was the aim of the present study to investi-
gate the effectiveness and mode of action on cardiovas-
cular system and sympathetic activity of these antihy-
potensive drugs injected i.v. in young volunteers with dif-
ferent grades of postural hypotension, induced by tilting. 
2. Patients and methods 
2.1. Patients and drugs 
The study was performed in 15 healthy volunteers (Table 1). 
They were informed about the nature and risks of the study and 
had given their written consent. The volunteers were allowed to 
withdraw of any time without giving reasons. The following par-
ameters should be fulfilled twice by the volunteers prior to the 
study: 
1. systolic blood pressure after 30 min supine < 130 mmHg; 
2. decrease in systolic blood pressure during passive orthostasis 
after tilting with feet lowered at 90 c: > 15 mmHg (this 
method for inducing orthostatic hypotension in described by 
de Marees et al. 1975 [11]); when collapse occurred, this re-
quirement was regarded as fulfilled; 
3. pressure-dependent venous capacity of one leg at 70 mmHg 
pressure: 4.5—5.5 ml/100 ml soft tissue. 
In a double-blind, intraindividual, and randomized order, the 
study was performed in volunteers receiving acute equieffective 
doses, equieffective with respect to the blood pressure, of 5 mg 
amezinium (CAS 30578-37-1), 0.5 mg dihydroergotamine (CAS 
511-12-6), 5 mg midodrine (CAS 42794-76-3) and 20 mg oxilof-
rine (CAS 365-26-4) intravenously (i.v.) within 2 min versus pla-
cebo. Between the drug administrations an interval of 7 days was 
maintained. Haemodynamic measurements were performed in 
Table 1: Data of patients. 
Number of patients 15 
Male 5 
Female 10 
Age (years) 22.4 + 3.1 
Weight (kg) 6 0 . 9 ± 8 . 5 
Height (cm) 171.9 + 6.6 
The values are given as mean ± standard deviation. 
the morning in a room with a temperature of 24 °C after at least 
12 h abstinence from alcohol and caffeine. Further informations 
to the products, e.g. names and Galch numbers are available 
from the authors. 
2.2. Blood pressure and heart rate 
Prior to investigation, an indwelling catheter was inserted into 
an antecubital vein of each volunteer. After 30 min supine, sam-
ples of 5 ml blood were taken for assay of curculating catechol-
amines (noradrenaline and adrenaline). 
Pressure-dependent venous capacity and resting values for blood 
pressure (RR = combined Riva-Rocci/Korotkoff method) and 
heart rate (via ECG) were determined. Resting blood pressure 
refers to the value taken immediately before tilting. Resting 
blood pressure after injection of the drugs investigated was ob-
tained 30 min after i.v. administration, immediately before tilt-
ing. During the subsequent 10 min of passive orthostasis (tilting 
table, feet lowered at 90 0 as described by [11]), blood pressure 
and heart rate were taken at 1-min intervals, and blood samples 
for plasma catecholamine assay were taken after the 1st, 2nd, 
5th, and 10th minute. 
2.3. Echocardiography 
Cardiac parameters were estimated by 2-D-echocardiographic 
sonography (Sonotron Diasonics LV 3400 R) and evaluated by 
Cardio 80 system (Kontron; Chapman's biplane method). E C G -
triggered enddiastolic and endsystolic silhouettes of the heart 
were determined after freezing and stroke volume, ejection frac-
tion and cardiac output were calculated and depicted as the in-
dices (ml/m2). 
The volunteers were then given the scheduled drug and the se-
quence of investigations described above was repeated 30 min 
later. 
2.4. Venous capacity 
The pressure-dependent venous capacity of the left lower leg was 
measured by using a Plethysmograph (VVP 300; Boucke, Tubin-
gen, FRG). Stepwise increase of the pressure in the left lower leg 
from 40 up to 100 mmHg causes an enlargement in the venous 
volume of this leg. The pressure-volume curve thus obtained was 
used to determine the venous capacity for a height-corrected 
pressure of 70 mmHg. 
2.5. Plasma catecholamines 
To determine the plasma catecholamine concentrations, 5 ml 
blood were taken through the venous catheter and placed in ice 
cold PP tubes containing EGTA/glutathione (20 ul/ml blood). 
Immediately after mixing, the blood samples were centrifuged 
for 10 min at 4 °C and 5000 x g and the plasma stored at —70 °C 
until assay. Noradrenaline and adrenaline were determined by 
high pressure liquid chromatography (HPLC) (Waters, West La-
fayette, USA) and electrochemical detection as described previ-
ously [5]. 
2.6. Statistical analysis 
During orthostasis the systolic and diastolic blood pressure val-
ues circumscribe areas above and/or below the respective resting 
pressure curves. These were calculated with the trapezoidal for-
mula and their absolute values added. The heart rate curve was 
evaluated during the orthostasis, the values recorded immedi-
ately before discontinuation were continued until the end of the 
test. 
The values of the random samples are given as mean ± S E M 
and were compared statistically by means of analysis of variance 
(ANOVA) and Student's t-test for paired differences. 
3. Results 
3.1. Blood pressure and heart rate 
The initial values for blood pressure and heart rate were 
comparable in the different groups (Table 2). Resting 
blood pressure was not influenced by administration 
of the different antihypotensive agents and placebo 
(Table 2). However, the resting heart rate decreased sig-
nificantly by 9, 8, 11, and 4 beats/min, respectively, after 
Table 2: Initial values of cardiovascular data. 
Blood pressure and heart rate 
Substance Before medication 
After medication 
SBP DBP HR SBP DBP HR 
(mmHg) (mmHg) (b/min) (mmHg) (mmHg) (b/min) 
Placebo 1 1 3 . 0 + 6.6 70.615.0 74.9+12.8 112.61 7.4 73.91 7.0 70.9111.6* 
Amezinium 113 .3 + 7.7 71.417.4 73.9112.8 116.9110.1 76.01 9.3 65.3112.0*** 
Dihy droergotami ne 112.117.0 71.9 + 7.0 70.4112.8 112.91 7.7 77.41 7.4 61.9110.8** 
Midodrine 111.5 + 9.3 71.117.0 74.7111.2 112.91 9.3 73.91 8.5 64.3110.5*** 
Oxilofrine 111 .9 + 7.7 70.518.1 73.3112.4 116.6110.1 72.3110.1 73.9112.0 
Abbrevations: SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate. The values are given as mean 1 standard deviation. 
Significance: * p < 0.05, ** p < 0.01, *** < 0.001. 
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Fig. 1: Blood pressure (BP) and heart rate (HR) during passive orthostasis 
before (open columns) and after (hatched columns) i.v. injection of the 
various antihypotensive agents. The columns represent the area criterions 
of the BP or HR curves (x min) during orthostasis (see methods). Abbre-
viations: PCB = placebo, D H E = dihydroergotamine, M D D = midodrine, 
O X F = oxilofrine, A M Z = amezinium. *p < 0.05, in comparison to the 
respective control. 
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Fig. 2: Enddiastolic (EDVI) and stroke volume index (SVI) as determined 
by cardio-sonographic measurements before (open columns) and after 
(hatched columns) i.v. injection of the various antihypotensive agents. Ab-
breviations see Fig. 1. *p < 0.05; **p < 0.01;***p < 0.001. The asterisks 
above the columns represent the significance versus the respective control, 
the asterisks within the columns show the significance versus placebo. 
injection of amezinium, dihydroergotamine, midodrine, 
and placebo. Oxilofrine did not change the heart rate (Ta-
ble 2). 
Also the changes in blood pressure observed during or-
thostasis are comparable for the different groups before 
administration of the drugs (Fig. 1). Only midodrine low-
ered significantly the area criterion of blood pressure 
when compared to the respective control, but not versus 
placebo (Fig. 1). 
Heart rates were also comparable before administration 
of the antihypotensive agents. After injection of the drugs 
and tilting no significant changes were observed (Fig. 1). 
3.2. Echocardiography 
Enddiastolic volume index was significantly enhanced 
against control and placebo by midodrine only. Also for 
amezinium and oxilofrine, a tendency for an increase in 
enddiastolic volume index in comparison to controls 
could be observed (Fig. 2). Stroke volume index was in-
creased by midodrine, oxilofrine and amezinium, when 
compared to the respective controls and placebo (Fig. 3). 
We did not observe any changes in endsystolic volume 
index (ESVI); therefore the ESVI-values are not depicted. 
As a parameter for myocardial contractility the ejection 
fraction was calculated. Oxilofrine and amezinium in-
creased significantly the ejection fraction. In addition, 
cardiac index was enhanced, but only after injection of 
oxilofrine (Fig. 3). 
3.3. Venous capacity 
The values of the pressure-dependent venous capacity be-
fore administration of the antihypotensive agents ranged 
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Fig. 3: Ejection fraction (EF) and cardiac index (CI) as calculated from 
enddiastolic and endsystolic silhouettes or from stroke volume and heart 
rate before (open columns) and after (hatched columns) i.v. injection of the 
various antihypotensive drugs. Abbreviations see Fig. 1. *p < 0.05, **p 
< 0.01. The asterisks above the columns represent the significance versus 
the respective control, the asterisks within the columns show the signifi-
cance versus placebo. 
between 4.0 and 5.02 ml/100 ml soft tissue (ST) and were 
comparable. Amezinium, midodrine, oxilofrine, and pla-
cebo did not influence the venous capacity. After dihy-
droergotamine, however, the venous capacity decreased 
significantly by 0.6 ml/100 ml ST (Fig. 4). 
3.4. Plasma catecholamines 
During resting in supine position mean circulating nor-
adrenaline (NA) in the volunteers before medication was 
approximately 200 pg/ml and was comparable for the 
5 groups (Fig. 5). After tilting noradrenaline concentra-
tions showed a typical pattern, obtained saturation 
curves reaching 490 — 570 pg/ml after 5 up to 10 min 
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Fig. 4: Venous capacity of the left lower leg at height corrected venous 
pressure of 70 mmHg before (hatched columns) and after (dotted columns) 
i.v. injection of the various antihypotensive drugs. ***p < 0.001 versus 
control and placebo. 
(Fig. 5). The noradrenaline curves after amezinium, ox-
ilofrine, and placebo showed no changes when compared 
to the respective curves before medication. However, 
dihydroergotamine reduced circulating noradrenaline 
significantly during all sampling times, whereas midod-
rine decreased N A significantly during the 2nd, 5th, and 
10th (only p < 0.1) minute of tilting (Fig. 5). Circulating 
adrenaline did not change under all experimental con-
ditions (not depicted). 
3.5, Side effects 
Note on subjective symptoms of volunteers in the study: 
Before and after administration of the various antihy-
potensive drugs the volunteers were asked for the follow-
Table 3: Symptoms during orthostasis. 
PCB A M Z D H E M D D O X F 
Vertigo 5+ 4+ 4+ 5+ 3+, 2 -
Scotodinia 1 + 1 + 2+ 2+ 2+ 
Tinnitus 1 + 
Palpitation 2+ 1 + 1 + 2+ 
Sweating stage 2+ 3+ 1 + 3+ 1+. 2 -
Congestion 
in the head 1 + 1 + 
1 + 
+ means improvement of the conditions under the respective drug. — 
means aggravation of the conditions. Abbreviations: PCB = placebo. A M Z 
= amezinium, D H E = dihydroergotamine. M D D = midodrine. O X F = ox-
ilofrine. 
ing symptoms during orthostasis: vertigo, scotodinia, tin-
nitus, palpitation, sweating stage and congestion in the 
head (Table 3). Moreover, the side effects during and af-
ter i.v. injection of the agents were observed: congestion 
in the head: placebo 1 x, dihydroergotamine 8 x, midod-
rine 2 x; palpitation: amezinium 1 x, oxilofrine 10 x; 
tiredness: dihydroergotamine 2 x, oxilofrine 1 x, sensa-
tion of coldness: amezinium 2 x, midodrine 2 x, oxilof-
rine 1 x; heat sensation: placebo 1 x, dihydroergotamine 
3 x, midodrine 1 x; dryness of the mouth: dihydroergo-
tamine 1 x; tingling of the scalp: dihydroergotamine 1 x, 
midodrine 7 x; analeptic effects: midodrine 1 x, oxilof-
rine 1 x; nausea: dihydroergotamine 4 x; pilo-erection: 
midodnne 1 x. 
It should be noted that even injection of placebo caused 
side effects and was able to improve the conditions ob-
served under tilting. Side effects only occurred during i.v. 
injections and lasted at the most for 30 min. 
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Fig. 5: Plasma noradrenaline concentrations before (0) and during 1. 2, 5 and 10 min of passive orthostasis. before treatment (•). after i.v. injection oi 
the various drugs (O). *p < 0.05. **p < 0.01, ***p < 0.001. 
4. Discussion 
The aim of the present study was to estimate the thera-
peutic value after acute administration of different anti-
hypotensive drugs on the basis of determination of car-
diac parameters by 2-D-echocardiography, venous Ple-
thysmographie measurements, and assay of circulating 
catecholamines with the help of high pressure liquid 
chromatography (HPLC). Also blood pressure and heart 
rate were recorded. As we could demonstrate blood pres-
sure and heart rate are not reliable parameters for estab-
lishing differences between the drugs investigated. There-
fore, echocardiographic data, venous plethysmography, 
and catecholamines as an index of sympathetic tone [3] 
have been used in order to differentiate the pharmaco-
logical actions of the various antihypotensive agents. 
The results of our study confirm earlier data for dihy-
droergotamine [9, 10]. Dihydroergotamine reduces the 
venous capacity of the lower leg indicating an increased 
venous tone. The decreased venous capacity is followed 
by an enhanced venous blood reflow to the heart and re-
sults in a possibly lower sympathetic tone in orthostasis 
(via baroreceptor reflex), clearly reflected by the reduced 
plasma noradrenaline concentration at all sampling times 
after injection of dihydroergotamine. The mechanism of 
action of dihydroergotamine was originally explained as 
an action at postsynaptically localized a-adrenoceptors of 
the veins. However, more recent in vitro studies have 
shown that tonicising of the leg veins in man after dihy-
droergotamine administration is induced almost exclu-
sively by an excitation of postsynaptic serotonin recep-
tors [ 12]. The decrease in circulating noradrenaline under 
resting conditions and in orthostasis could be explained 
as a consequence from both, stimulation of presynaptic 
a-adrenoceptors and of serotonin receptors, reducing 
noradrenaline release by a negative feed-back mechanism 
[16]. 
In contrast to the effects of sympathomimetic drugs like 
midodrine and oxilofrine, dihydroergotamine obviously 
did not change the cardiac parameters measured in our 
study. The diminished sympathetic tone (c.f. Fig. 5, re-
flected by decreased plasma noradrenaline concentra-
tions) in combination with the tonicising action of di-
hydroergotamine on the a-adrenoceptors and serotonin 
receptors of the leg veins are probably responsible for the 
unchanged cardiac parameters. 
Pharmacodynamic investigations have classified midod-
rine as an a-sympathomimetic drug [13]. We were able 
to confirm these findings while observing effects, mainly 
classified as actions on post- and presynaptic a-adreno-
ceptors. The stimulation of postsynaptic a-adrenoceptors 
is suggested by the reflex bradycardia. The reduced 
plasma noradrenaline concentrations observed during or-
thostasis indicated an action on presynaptic a-adreno-
ceptors. Midodrine had no influence on venous capacity. 
This finding could support further evidence that leg veins 
in man are tonicised mainly by stimulation of serotonin 
receptors [12]. The described increase in central venous 
pressure after midodrine could therefore be due to toni-
cising of the veins of the splanchnic or thoracic region, 
as observed after administration of etilefrine [2] (cf. also 
discussion on amezinium). The latter effects could be also 
responsible for the observed increase in enddiastolic vol-
ume and stroke volume (cf. Fig. 2). 
Clinical pharmacology studies on oxilofrine [1] allow this 
compound to be classified as a ß-sympathomimetic drug, 
ß-sympathomimetic agents have a positive inotropic and 
chronotropic action on the heart. Non-specific ß-sympa-
thomimetic drugs (with ß r /ß 2 -adrenergic effects) can 
moreover dilate arterioles and venoles by stimulating 
vascular ß 2-adrenoceptors and therefore decrease the pe-
ripheral resistance. 
Our results are compatible with this classification, show-
ing a distinct action of oxilofrine on cardiac parameters, 
i.e. increase in stroke volume, ejection fraction, and car-
diac index, parameters for myocardial contractility. 
Amezinium is an indirect sympathomimetic drug which 
also acts directly on a-adrenoceptors [6, 8, 12]. However, 
indirect sympathomimetic effects (significant increase in 
circulating noradrenaline) have been observed after in-
jection of 10 mg i.v. (Grobecker 1977, unpublished ob-
servations). After amezinium, a pronounced reflex de-
crease in heart rate occurred under resting conditions in-
dicating an a-sympathomimetic activity. The results of 
the plasma noradrenaline assay could not confirm an in-
direct sympathomimetic effect of amezinium in the low 
dose injected (5 mg). However, cardiac parameters for 
contractility were increased (stroke volume and ejection 
fraction, cf. Fig. 2 and 3) probably indicating a release of 
myocardial noradrenaline by amezinium. 
Since an increase in central venous pressure was observed 
after acute amezinium doses, it is conceivable that the 
blood volume required for this effect is mobilized from 
the veins of the splanchnic or thoracic region. This effect 
has recently been described for etilefrine [2]. 
The data available appear to allow a differential estima-
tion of the therapeutic value of the drugs investigated for 
pharmacotherapy of orthostatic dysregulation. Accord-
ing to the scheme of Thulesius 1976 [17] for differential 
diagnosis of orthostatic dysregulation, the sympathotonic 
reaction (rise in heart rate, fall in systolic blood pressure, 
rise in diastolic blood pressure, reduction of stroke vol-
ume by about 51 %) is the most frequent, i.e. about 70 %, 
of all forms of postural hypotension. If this type of hy-
potension is present and associated with sequestration of 
blood volume in the leg veins, dihydroergotamine ap-
peared to be the most suitable drug for therapy. If, how-
ever, the blood volume is displaced more into the region 
of the splanchnic or thoracic region, treatment with mi-
dodrine should be recommended. 
The asympathotonic reaction according to Thulesius [1 7] 
(decrease in systolic and diastolic blood pressure, reduc-
tion of stroke volume by about 28 %, heart rate remains 
unchanged) appeared to be an indication for amezinium 
and oxilofrine. Because of their mechanisms of action, 
both drugs are able to increase the sympathetic tone by-
stimulating cardiovascular a-and ß-adrenoeeptors. 
This study does not provide any data about the effect of 
the drugs investigated after chronic oral administration 
in patients with orthostatic dysregulation. In a forthcom-
ing paper this issue will be investigated and the thera-
peutic value of the drugs reevaluated. 
On the other hand we failed to observe reproducible or-
thostatic reactions in our volunteers, despite the subjects 
fulfilled the criteria of "orthostatic dysregulation" de-
scribed under methods, when proofed prior to the inves-
tigation schedule. It is a well known physiological fact 
that orthostatic hypotension or dysregulation depends on 
room temperature, psychical behaviour, and climate con-
ditions, etc.; those changes in external conditions could 
also contribute to a non-reproducible orthostatic reac-
tion. 
Therefore a careful selection of patients exhibiting or-
thostatic dysregulation is needed in studies concerning 
orthostatic dysregulations. 
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